PT2019104E - Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica - Google Patents

Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica

Info

Publication number
PT2019104E
PT2019104E PT72909047T PT07290904T PT2019104E PT 2019104 E PT2019104 E PT 2019104E PT 72909047 T PT72909047 T PT 72909047T PT 07290904 T PT07290904 T PT 07290904T PT 2019104 E PT2019104 E PT 2019104E
Authority
PT
Portugal
Prior art keywords
therapeutic use
cytotoxic agents
tomaymycin derivatives
new
new tomaymycin
Prior art date
Application number
PT72909047T
Other languages
English (en)
Inventor
Laurence Gauzy
Yonghong Deng
Herve Bouchard
Ravi V J Chari
Alain Commercon
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39048765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2019104(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PT2019104E publication Critical patent/PT2019104E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
PT72909047T 2007-07-19 2007-07-19 Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica PT2019104E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07290904.7A EP2019104B1 (en) 2007-07-19 2007-07-19 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use

Publications (1)

Publication Number Publication Date
PT2019104E true PT2019104E (pt) 2013-12-03

Family

ID=39048765

Family Applications (2)

Application Number Title Priority Date Filing Date
PT72909047T PT2019104E (pt) 2007-07-19 2007-07-19 Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
PT08826772T PT2170890E (pt) 2007-07-19 2008-07-18 Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT08826772T PT2170890E (pt) 2007-07-19 2008-07-18 Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica

Country Status (39)

Country Link
US (1) US8404678B2 (pt)
EP (2) EP2019104B1 (pt)
JP (1) JP5551070B2 (pt)
KR (1) KR101627871B1 (pt)
CN (1) CN101784550B (pt)
AR (1) AR067575A1 (pt)
AT (1) ATE530553T1 (pt)
AU (1) AU2008281439B2 (pt)
BR (1) BRPI0814267A2 (pt)
CA (1) CA2693551C (pt)
CL (1) CL2008002139A1 (pt)
CO (1) CO6290692A2 (pt)
CR (1) CR11225A (pt)
CY (2) CY1112278T1 (pt)
DK (2) DK2019104T3 (pt)
DO (1) DOP2010000014A (pt)
EA (1) EA019938B1 (pt)
EC (1) ECSP109875A (pt)
ES (2) ES2435779T3 (pt)
GT (1) GT201000008A (pt)
HR (1) HRP20120067T1 (pt)
IL (1) IL203318A (pt)
JO (1) JO2744B1 (pt)
MA (1) MA31617B1 (pt)
ME (1) ME00969B (pt)
MY (1) MY151245A (pt)
NI (1) NI201000005A (pt)
NZ (1) NZ582679A (pt)
PA (1) PA8790201A1 (pt)
PE (2) PE20130590A1 (pt)
PL (2) PL2019104T3 (pt)
PT (2) PT2019104E (pt)
RS (1) RS52245B (pt)
SI (2) SI2019104T1 (pt)
TN (1) TN2010000002A1 (pt)
TW (1) TWI500618B (pt)
UA (1) UA98153C2 (pt)
WO (1) WO2009016516A2 (pt)
ZA (1) ZA201000389B (pt)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3826769A1 (de) 1988-08-06 1990-02-15 Bayer Ag Behandlung von polyamidfasern
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
JP5489997B2 (ja) 2007-07-19 2014-05-14 シマベイ セラピューティクス, インコーポレーテッド 糖尿病および代謝疾患の治療のためのRUP3またはGPRl19受容体のアゴニストとしてのN−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
DE102008056086A1 (de) * 2008-11-06 2010-05-12 Gp Solar Gmbh Additiv für alkalische Ätzlösungen, insbesondere für Texturätzlösungen sowie Verfahren zu dessen Herstellung
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
AU2015224492B2 (en) * 2009-02-05 2017-04-20 Immunogen, Inc. Novel benzodiazepine derivatives
EP2437790B1 (en) 2009-06-03 2019-02-20 Immunogen, Inc. Conjugation methods
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
JP5870400B2 (ja) 2010-04-15 2016-03-01 シアトル ジェネティクス,インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
WO2011130598A1 (en) * 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
ES2623057T3 (es) 2010-04-15 2017-07-10 Medimmune Limited Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
EP2585048B1 (en) 2010-06-23 2018-04-11 CymaBay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
KR20140010076A (ko) * 2011-02-15 2014-01-23 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체
TR201902180T4 (tr) 2011-03-29 2019-03-21 Immunogen Inc Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
US9156854B2 (en) 2011-04-18 2015-10-13 Immunogen, Inc. Maytansinoid derivatives with sulfoxide linker
SG11201400770SA (en) 2011-09-20 2014-04-28 Spirogen Sarl Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
SG11201401021TA (en) 2011-10-14 2014-08-28 Spirogen Sarl Pyrrolobenzodiazepines
CN103998449A (zh) 2011-10-14 2014-08-20 斯皮罗根有限公司 吡咯并苯并二氮杂卓
MX358757B (es) 2011-10-14 2018-09-03 Seattle Genetics Inc Pirrolobenzodiazepinas y conjugados dirigidos.
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
AU2012352210A1 (en) * 2011-12-13 2014-07-24 Immunogen, Inc. Use of N-hydroxysuccinimide to improve conjugate stability
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
BR112014027166A2 (pt) 2012-05-01 2017-06-27 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
AR091700A1 (es) 2012-07-09 2015-02-25 Genentech Inc Anticuerpos e inmunoconjugados anti-cd79b
CN104540524A (zh) 2012-07-09 2015-04-22 基因泰克公司 包含抗cd22抗体的免疫缀合物
RU2015106673A (ru) 2012-08-02 2016-09-20 Дженентек, Инк. Антитела к рецептору эндотелина типа в (etbr) и иммуноконъюгаты
HK1211208A1 (zh) 2012-08-22 2016-05-20 Immunogen, Inc. 細胞毒性苯並二氮呯衍生物
RU2661083C2 (ru) * 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
ES2649990T3 (es) 2012-10-12 2018-01-16 Medimmune Limited Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
BR112015008251B1 (pt) 2012-10-12 2023-09-26 Medimmune Limited Pirrolobenzodiazepinas, conjugados destas, composição e composição farmacêutica compreendendo os conjugados, uso dos conjugados para o tratamento de uma doença proliferativa e método para preparar os conjugados
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
US9745303B2 (en) 2012-10-12 2017-08-29 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
DK2968494T3 (en) 2013-03-13 2019-03-04 Seattle Genetics Inc ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs
AU2014244245C1 (en) * 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
CN105142674B (zh) * 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
EP3299391B1 (en) 2013-03-14 2019-12-04 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP6993084B2 (ja) 2013-08-12 2022-02-03 ジェネンテック, インコーポレイテッド 1-(クロロメチル)-2,3-ジヒドロ-1h-ベンゾ[e]インドール二量体抗体 - 薬物コンジュゲート化合物、並びに使用及び処置の方法
MX2016003248A (es) 2013-09-17 2016-06-07 Genentech Inc Metodos de uso de anticuerpos anti-lgr5.
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CA2931340A1 (en) 2013-12-13 2015-06-18 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
EP3082876B1 (en) 2013-12-16 2018-01-17 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
EP3145952A2 (en) 2014-05-22 2017-03-29 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
PT3189056T (pt) 2014-09-03 2020-09-04 Immunogen Inc Derivados citotóxicos de benzodiazepina
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN113698488A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
MY186334A (en) 2014-09-12 2021-07-12 Genentech Inc Anti-her2 antibodies and immunoconjugates
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
CN107124870A (zh) * 2014-09-17 2017-09-01 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
EP3223854A1 (en) * 2014-11-25 2017-10-04 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
KR20170102981A (ko) 2015-01-14 2017-09-12 브리스톨-마이어스 스큅 컴퍼니 헤테로아릴렌-가교된 벤조디아제핀 이량체, 그의 접합체, 및 제조 및 사용 방법
MX2017009145A (es) 2015-01-14 2017-11-22 Bristol Myers Squibb Co Dimeros de benzodiazepina, conjugados de estos, y sus metodos de preparacion y uso.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
CN108391434A (zh) 2015-06-23 2018-08-10 百时美施贵宝公司 大环苯并二氮杂*二聚体、其缀合物、制备和用途
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
SMT202000004T1 (it) 2015-07-21 2020-03-13 Immunogen Inc Metodi di preparazione dei derivati citotossici di benzodiazepina
WO2017049296A1 (en) 2015-09-20 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
WO2017064675A1 (en) 2015-10-16 2017-04-20 Genentech, Inc. Hindered disulfide drug conjugates
WO2017107817A1 (zh) * 2015-12-21 2017-06-29 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
AU2017248644B2 (en) 2016-04-15 2019-10-31 Bioatla, Llc Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
TWI851939B (zh) 2016-05-13 2024-08-11 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック, インコーポレイテッド 部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CN107469089B (zh) * 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
US11066479B2 (en) 2016-08-02 2021-07-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
EP3493807A1 (en) 2016-08-03 2019-06-12 CymaBay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
EP3496763B1 (en) 2016-08-11 2026-04-01 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
CA3036983A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
TWI755450B (zh) 2016-11-23 2022-02-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
AU2017382883B2 (en) 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
SI3558391T1 (sl) 2016-12-23 2022-06-30 Immunogen, Inc. Imunokonjugati, ciljno usmerjeni na ADAM9, in načini njihove uporabe
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
CN110536703B (zh) 2017-04-20 2024-07-12 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
WO2018213064A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
RS62928B1 (sr) 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
SG11202001430SA (en) 2017-09-29 2020-04-29 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2020014482A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
EP3833684A1 (en) 2018-08-08 2021-06-16 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
WO2020102777A1 (en) 2018-11-16 2020-05-22 Virtuoso Binco, Inc. Cd38 and icam1 antibodies and uses thereof
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
US20220096641A1 (en) * 2019-01-03 2022-03-31 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
AU2020206308B2 (en) 2019-01-08 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
CA3125033A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
ES2967878T3 (es) 2019-03-15 2024-05-06 Medimmune Ltd Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
EP3947395A1 (en) 2019-03-29 2022-02-09 ImmunoGen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
US12552865B2 (en) 2019-10-22 2026-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting B7-H3 (CD276) for treating multiple solid tumors
JP7835441B2 (ja) 2019-12-06 2026-03-25 トゥルーバインディング,インコーポレイテッド Gal3とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
CA3161573A1 (en) 2019-12-12 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for cd276 and uses thereof
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2021195469A1 (en) 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
AU2022291120A1 (en) 2021-06-09 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング,インコーポレイテッド タンパク質凝集を防止する方法
MX2024003266A (es) 2021-09-16 2024-04-03 Avidity Biosciences Inc Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
AU2022388722A1 (en) 2021-11-09 2024-05-23 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
PE20242350A1 (es) 2022-05-03 2024-12-16 Genentech Inc Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
AU2024295016A1 (en) 2023-07-20 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2076465C (en) * 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
PT1109812E (pt) 1998-08-27 2005-09-30 Spirogen Ltd Pirrolobenzodiazepinas
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
ES2276708T3 (es) * 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
EP1608663B1 (en) * 2003-03-31 2008-11-05 Council of Scientific and Industrial Research Pyrrolo (2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
WO2004091542A2 (en) 2003-04-15 2004-10-28 Covx Pharmaceuticals, Inc. Nitrogen containing integrin targeting compounds
KR101672664B1 (ko) 2003-07-21 2016-11-04 이뮤노젠 아이엔씨 인간화된 항체 또는 그의 항원결정기 결합절편
GB0321295D0 (en) * 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
ATE516288T1 (de) * 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404578D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
EP1723152B1 (en) 2004-03-09 2015-02-11 Spirogen Sàrl Pyrrolobenzodiazepines
GB0410725D0 (en) * 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
ATE527262T1 (de) * 2006-01-25 2011-10-15 Sanofi Sa Neue tomaymycin derivate enhaltende zytotoxische mittel
EA020324B1 (ru) * 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
JO2744B1 (en) 2014-03-15
TW200922598A (en) 2009-06-01
CL2008002139A1 (es) 2009-10-23
PA8790201A1 (es) 2009-02-09
CA2693551C (en) 2016-09-20
NI201000005A (es) 2010-03-09
WO2009016516A3 (en) 2009-06-11
MY151245A (en) 2014-04-30
US20100316656A1 (en) 2010-12-16
EA201070163A1 (ru) 2010-08-30
ES2376026T3 (es) 2012-03-08
CY1114922T1 (el) 2016-12-14
KR101627871B1 (ko) 2016-06-07
CA2693551A1 (en) 2009-02-05
CY1112278T1 (el) 2015-12-09
PT2170890E (pt) 2012-02-03
PE20090889A1 (es) 2009-08-06
DK2170890T3 (da) 2012-02-27
AU2008281439A1 (en) 2009-02-05
CO6290692A2 (es) 2011-06-20
DOP2010000014A (es) 2010-02-15
EP2019104A1 (en) 2009-01-28
ECSP109875A (es) 2010-02-26
JP5551070B2 (ja) 2014-07-16
UA98153C2 (uk) 2012-04-25
TN2010000002A1 (en) 2011-09-26
KR20100063021A (ko) 2010-06-10
RS52245B (sr) 2012-10-31
BRPI0814267A2 (pt) 2015-03-31
SI2170890T1 (sl) 2012-02-29
US8404678B2 (en) 2013-03-26
CR11225A (es) 2010-06-23
MA31617B1 (fr) 2010-08-02
CN101784550B (zh) 2014-06-11
AR067575A1 (es) 2009-10-14
EP2170890B1 (en) 2011-10-26
HRP20120067T1 (hr) 2012-02-29
PL2019104T3 (pl) 2014-03-31
AU2008281439B2 (en) 2013-02-07
ATE530553T1 (de) 2011-11-15
DK2019104T3 (da) 2013-12-16
ME00969B (me) 2012-06-20
NZ582679A (en) 2012-04-27
IL203318A (en) 2016-08-31
EP2170890A2 (en) 2010-04-07
JP2010533703A (ja) 2010-10-28
TWI500618B (zh) 2015-09-21
ES2435779T3 (es) 2013-12-23
WO2009016516A2 (en) 2009-02-05
SI2019104T1 (sl) 2013-12-31
ZA201000389B (en) 2011-04-28
WO2009016516A8 (en) 2009-04-16
EA019938B1 (ru) 2014-07-30
GT201000008A (es) 2012-03-26
PL2170890T3 (pl) 2012-04-30
PE20130590A1 (es) 2013-05-22
EP2019104B1 (en) 2013-09-04
HK1144289A1 (en) 2011-02-11
CN101784550A (zh) 2010-07-21

Similar Documents

Publication Publication Date Title
WO2009016516A3 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
PL1761542T3 (pl) Pochodne oktahydropirolo[3,4-c]pirolu i ich zastosowanie jako środków przeciwwirusowych
WO2007018998A3 (en) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
MX2009002995A (es) Derivados de pirazolo-[1,5-a]-pirimidina y su uso terapeutico.
GEP20135780B (en) Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
MY153921A (en) Aminopyrazole derivatives
WO2006126082A3 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2010124042A3 (en) Modulators of 5-ht receptors and methods of use thereof
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
WO2008116815A3 (en) Compounds
WO2007050587A3 (en) Therapeutic compositions and methods
IL196107A0 (en) PRODRUGS OF-5-AMINO-3-(3'-DEOXY-??-D-RIBOFURANOSYL)-THIAZOLO[4,5-d]PYRIMIDIN-2,7-DIONE
ZA200907416B (en) Pyrimido [4,5-D] azepine derivatives as 5-HT2C agonists
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
WO2009034547A3 (en) New 4-substituted derivatives of pyrazolo[3,4-d pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof
UA92021C2 (ru) Производные пиридо[2,3-d]пиримидина, их получение, их применение в терапии
IL190675A0 (en) Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
GB2434795A (en) Pyrrolo [2, 1-C] [1, 4] benzodiazepine-anthraquinone conjugates useful as antitumour agents